


CHC Healthcare Group (4164TT) 2025 2nd Investor Conference

2025/11/25

- This document is provided by CHC Healthcare Group (CHC). Information contained in this document has not been audited or reviewed by any accountants or independent experts. CHC makes no express or implied representations or warranties as to the fairness, accuracy, completeness, or correctness of such information or opinions.
- This document is provided as of the date herein and will not be updated to reflect any changes hereafter. CHC, its affiliates and their representatives do not accept any responsibility or liability for any damage caused by their negligence or any other reasons, nor do they accept responsibility or liability for any loss or damages arising from the use of this document or the information contained herein or anything related to this document.
- This document may contain forward-looking statements, including but not limited to all statements that address activities, events or developments that CHC expects or anticipates to take place in the future based on the projections of CHC toward the future, and various factors and uncertainty beyond CHC's control. Therefore, the actual results may differ materially from those contained in the forward-looking statements.
- This document is not and cannot be construed as an offer to purchase or sell securities or other financial products or solicitation of an offer.
- This document may not be directly or indirectly reproduced, redistributed or forwarded to any other person and may not be published in whole or in part for any purpose.




**Company
Overview**

**Business
Results**

**Latest
Updates**

**Future
Guidance**



**Company
Overview**

**Business
Results**

**Latest
Updates**


**Future
Guidance**

Basic Information


- **Company name:** CHC Healthcare Group
- **Company code:** 4164 TT
- **Date of establishment:** 2009/11/27
(1st subsidiary, Chiu Ho Instruments & Reagents, was founded in 1977)
- **Chairman:** Mr. Tien-Ying, Lee
- **President :** Mr. Pei-Lin, Lee
- **Headquarters :** Taipei
- **Branches :** Taichung, Kaohsiung, Guangzhou, Beijing, Shenyang, Jakarta, London
- **Paid-in capital:** NT\$ 1,953,109,890
- **Date of listing:** 2012/10/24




Milestones



Business Scope




Medical Equipment Distribution



Medical Management Service



Led by TW medical authorities
Manufacturer certified team
Nearly 100 engineers trained



Diversification of Business - Chain Pharmacy Channel



- Community chain pharmacies
- Comprehensive products & professional consulting service
- Health care for all ages

 **Everyone's Good Neighbor**



Prescription Medicine



Aesthetic Medicine



Weight Management



Baby Essentials



Elderly Supplies



LTC 2.0 Service

Diversification of Business - Irradiation Service

SAFE



PRECISE



ECO-FRIENDLY



SUSTAINABILITY


30% of energy savings

EFFICIENT



STABLE





**Company
Overview**


**Business
Results**

**Latest
Updates**


**Future
Guidance**

Operating Revenue


Operating revenue
(NT\$ thousand)



Product Mix





Profitability



Earnings Distribution

	Cash dividends per share (NT\$)	Basic EPS (NT\$)	Payout ratio
2020	2.01	2.53	79%
2021	2.011	2.43	83%
2022	2.01	2.21	91%
2023	2.01	2.55	79%
2024	1.51	1.01	150%





**Company
Overview**

**Business
Results**

**Latest
Updates**

**Future
Guidance**

Precision Medicine - Versa HD® & Harmony



Precision Medicine - Elekta Evo



Adapt at your rhythm



The only CT-Linac that uniquely evolves on your terms and offers everything from the everyday to the extraordinary.



Precision Medicine - Elekta MR Linac




 **Elekta**

Elekta Unity

Two worlds,
one future.

Precision Medicine - IBA Proton Therapy

Iba



45⁺% MARKET SHARE

IN PROTON THERAPY

80⁺ PROTON CENTERS

POWERED BY IBA

140,000⁺ PATIENTS


TREATED ON IBA EQUIPMENT

Precision Medicine - Baxter Integrated Solution in da Vinci Surgery

Baxter



Precision Medicine - Leica Hybrid 3D Surgical Microscope




Leica
MICROSYSTEMS



Precision Medicine - BVI Trifocal Hydrophobic Toric IOL



Health Industry - Chain Pharmacy Channel Network



Health Industry - Chain Pharmacy Channel Network



Veterinary Care




Private Label




Exclusive Distributor

Irradiation Business - Workflow

Irradiation Process (E-Beam & X-Ray)




Laboratory Testing



Applications of Irradiation



- Bacteria elimination
- Germination inhibition
- Shelf life extension





- Bioburden reduction
- Sterility assurance
- Infection risk avoidance



- Crosslinking
- Material modification
- Resistance reinforcement

- Semi-conductors switching-time improvement
- Aerospace material resistance testing
- Gemstone color enhancement
- Postal mail decontamination...





**Company
Overview**

**Business
Results**

**Latest
Updates**

**Future
Guidance**

Elderly Care Business



Taiwan + Japan

- Day care center
- Residential institution
- Rehabilitation hospital


Integrating Elderly
& Medical Care



Groundbreaking Ceremony for Elderly Care Park



BNCT - Neutron Therapeutics



BNCT - Neutron Therapeutics

nuBeam® exceeds IAEA reference values for beam quality

	Epithermal Flux $\Phi_{\text{epi}} 0.5\text{eV} < E_n < 10\text{keV}$ (n/cm ² /s)	Fast Neutron Contamination $D\Phi_f/\Phi_{\text{epi}}$ (Gy/cm ² /n)	Thermal Neutron Contamination $\Phi_{\text{thermal}}/\Phi_{\text{epi}}$	Gamma Contamination $D_\gamma/\Phi_{\text{epi}}$ (Gy/cm ² /n)	Beam Collimation J/ Φ
IAEA Recommends	$\geq 1 \times 10^9$	$\leq 7 \times 10^{-13}$	$\leq 5\%$	$\leq 2 \times 10^{-13}$	≥ 0.7
nuBeam 14 cm Aperture	1.4×10^9	1.0×10^{-13}	1.2%	1.6×10^{-13}	0.74

Neutron Therapeutics **nuBeam®** BNCT product features

- 2.6 MeV electrostatic proton accelerator
- Reliable operation at 30 mA for high patient throughput
- Rotating Solid Lithium Target: excellent lifetime and automated service minimize cost of ownership




BNCT - Neutron Therapeutics

	Neutron Therapeutics	Sumitomo	Dawon Medax	Heron Neutron Medical
Target	Li	Be	Be	Be
Proton energy	2.6 MeV	30 MeV	10 MeV	30 MeV
Beam current	30 mA (max 40 mA)	1 mA	2 mA	1 mA
Neutron yield	78 kW (max 104 kW)	30 kW	20 kW	30 kW
Accelerator based	DC Electrostatic	Cyclotron	RFQ-DLT	Cyclotron
IGRT (CT guide)	V	X	X	X
CE mark	Working in progress	X	X	X
Installed base	3	2	0	1
Designed & manufactured in-house	V	V	V	X

BNCT - Neutron Therapeutics

1st Clinical Application of Accelerator-Based BNCT in the West


- On May 16, 2025, Helsinki University Hospital (HUS) and Neutron Therapeutics issued a joint press release.
- Ongoing treatment for patients with inoperable, locally recurrent head and neck cancer using Neutron Therapeutics' **nuBeam®** accelerator-based BNCT
- HUS has been conducting BNCT treatments using a reactor since 1992 and accumulated more than 200 treated patients. **nuBeam®** is the first in-hospital BNCT accelerator system in the Western world.



PRESS RELEASE - PUBLISHED ON 16.5.2025, 08:31

BNCT treatments for cancer patients have started as part of a clinical trial

Neutron Therapeutics and Helsinki University Hospital Treat First Head and Neck Cancer Patients Using Accelerator-Based Boron Neutron Capture Therapy



BNCT - Neutron Therapeutics

A Phase 1 Clinical Trial to Treat 10 Patients

- Patient: recurrent cancer in the head and neck area
- Treatment: The nuBeam Suite + Boron carrier drug

The nuBeam Suite is a complete BNCT solution, including:

- ✓ A neutron source
- ✓ Patient positioning & imaging capabilities (CT inside the treatment room)
- ✓ Treatment control software
- ✓ Treatment planning software (combine with RayStation TPS)



BNCT - Neutron Therapeutics

Neutron Therapeutics' International Presence



- Shonan Kamakura General Hospital (SKGH) in Japan

Successful generation of a high-current proton beam and neutron beam at the **nuBeam®** system at SKGH, and will enter the clinical trial phase in Japan.

- Aviko Radiopharmaceuticals **AVIKO** / Leo Cancer Care  **LEO**

With the goal of establishing the first BNCT center in the United States, collaborating with Aviko to develop boron carrier drugs for BNCT, and working with Leo Cancer Care to develop a vertical patient-positioning system since 2023.

- High Flux Accelerator-Driven Neutron Facility Based at the University of Birmingham

The **nuBeam®** accelerator is also used at the University of Birmingham's High Flux Accelerator-Driven Neutron Facility, supporting fundamental studies in materials science, nuclear energy, and BNCT.



Thank you!



www.chcg.com

Copyright © 2019 CHC Limited. All rights reserved.